摘要
【摘 要】目的：对替洛非班在急性冠脉综合征患者治疗中的应用方式以及疗效进行详细探究。方法：在本次研究中，选择本院 2017年 9月～ 2018年 9月收治的急性冠脉综合征患者共 40例参与研究，并依据治疗方案差异，将患者分为对照组以及观察组。对于 20例观察组患者，应用常规治疗措施，而对于 20例观察组患者，在此基础上联合应用替洛非班。对两组患者 TIMI分级情况、出血情况以及急性或亚急性血栓事件发生情况进行统计和比较。结果：在对两组患者采用不同的治疗方案后，观察组中 TIMI血流 0级、 1级、 2级以及 3级数量均明显少于对照组患者，另外，观察组患者急性血栓事件发生率以及亚急性血栓事件发生率均为 0%，明显低于对照组患者急性血栓事件发生率以及亚急性血栓事件发生率（ 1/20） 5.0%、（ 1/20） 5.0%，组间差异显著， P<0.05，差异显著，具有统计学意义。结论：在对急性冠脉综合征患者进行治疗时，可采用替洛非班，可有效改善患者冠脉血流，同时降低血栓发生率，值得推广应用。
【关键词】急性冠脉综合征；替洛非班； TIMI血流；血栓
[Abstract] Objective: To explore the application and effect of tirofiban in the treatment of acute coronary syndrome. Methods: in this study, 40 patients with acute coronary syndrome admitted to our hospital from September 2017 to September 2018 were selected to participate in the study. According to the difference of treatment plan, the patients were divided into control group and observation group. For 20 patients in the observation group, routine treatment measures were used, while for 20 patients in the observation group, tirofiban was combined on this basis. TIMI grading, bleeding and acute or subacute thrombotic events were compared between the two groups. Results: the TIMI blood flow in the observation group was significantly less than that in the control group after different treatment. In addition, the incidence of acute thrombotic events and subacute thrombotic events in the observation group was 0%, significantly lower than that in the control group (1 / 20). 0%, (1 / 20) 5.0%, the difference between the groups was significant, P < 0.05, the difference was significant, with statistical significance. Conclusion: tirofiban can be used in the treatment of acute coronary syndrome, which can effectively improve the coronary blood flow and reduce the incidence of thrombosis.
出版日期
2020年08月18日（中国期刊网平台首次上网日期，不代表论文的发表时间）
